Antitumor activity and toxicity of NSC 314622 and MJ-III-65 in nude mice bearing human A253 and FaDu head and neck xenografts
| Treatment | MWL | MTGI | TDT | |
|---|---|---|---|---|
| mg/kg/week | % | days | ||
| A253 | ||||
| Control | 0 | 3.4 ± 0.4 | ||
| NSC 314622 | 5 | 3.6 ± 2.2 | 64.2 ± 3.2 | 7.8 ± 0.7 |
| NSC 314622 | 10 | 3.4 ± 1.1 | 65.6 ± 4.2 | 8.0 ± 0.9 |
| MJ-III-65 | 10 | 2.8 ± 2.0 | 56.1 ± 11.4 | 8.2 ± 1.2 |
| MJ-III-65 | 25 | 4.9 ± 1.9 | 66.8 ± 7.9 | 8.8 ± 1.0 |
| MJ-III-65 | 50 | 5.2 ± 1.6 | 71.8 ± 4.2 | 9.2 ± 1.2 |
| FaDu | ||||
| Control | 0 | 3.2 ± 0.5 | ||
| NSC 314622 | 5 | 3.6 ± 2.2 | 63.5 ± 4.4 | 7.9 ± 1.0 |
| NSC 314622 | 10 | 3.4 ± 1.1 | 66.4 ± 5.2 | 8.2 ± 1.5 |
| MJ-III-65 | 10 | 2.8 ± 2.0 | 56.6 ± 10.7 | 8.1 ± 1.0 |
| MJ-III-65 | 25 | 4.9 ± 1.9 | 66.2 ± 5.2 | 8.6 ± 0.8 |
| MJ-III-65 | 50 | 5.2 ± 1.6 | 69.0 ± 3.5 | 9.0 ± 1.0 |
MTGI, maximum tumor growth inhibition; MWL, maximum weight loss of pre-treatment body weight; TDT, tumor doubling time.